Immunic Appoints Elena Ridloff to Board
Analysis based on 6 articles · First reported Aug 10, 2026 · Last updated Aug 10, 2026
The appointment of a seasoned financial executive to the board is a modest positive signal for Immunic, potentially enhancing investor confidence as the company approaches key clinical milestones. The market impact is limited, as board appointments typically have a minor effect on stock price, but the timing near a Phase 3 readout could amplify sentiment.
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company developing oral therapies for neurologic diseases, announced the appointment of Elena Ridloff, CFA, to its Board of Directors, effective August 6, 2026. Ridloff brings over two decades of experience in finance, capital markets, and commercial leadership in the biopharmaceutical industry. She currently serves as CFO of Sionna Therapeutics and previously held senior roles at Acadia Pharmaceuticals, AstraZeneca — Alexion Pharmaceuticals, Biovisio, and Maverick Capital. She also serves on the board of Kymera Therapeutics and previously served on the board of Kronos Bio. The appointment comes as Immunic approaches pivotal Phase 3 ENSURE readout in relapsing multiple sclerosis, with top-line data expected by year-end 2026, and plans to initiate a confirmatory Phase 3 program in progressive MS. The company aims to leverage Ridloff's expertise to support its growth and commercialization efforts.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard